Redness, peeling, pain and cracking of the palms and soles caused by certain chemotherapy pills and by kinase inhibitors that block blood vessel growth. Rarely dangerous but can stop patients walking or using their hands.
Hand-foot syndrome from capecitabine, 5-FU infusion and liposomal doxorubicin is a diffuse painful erythema; hand-foot skin reaction from VEGFR multikinase inhibitors (sorafenib, regorafenib, cabozantinib, lenvatinib) is more localised hyperkeratotic callus over pressure points. Both are dose-dependent, managed by dose interruption and reduction, urea creams, and avoiding friction and heat; celecoxib and pyridoxine have weak evidence. It is one of the most common reasons for dose reduction of oral therapies and a leading contributor to quality-of-life loss on long-term TKIs.
Showing the molecule this term concerns: Sorafenib.
Shares Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel, Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies, DPYD genotyping and DPD phenotyping before fluoropyrimidines, Pancreatic ductal adenocarcinoma.
Shares SYSUCC-001, CREATE-X, Triple-negative breast cancer (TNBC).
Shares Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation), Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel, Pancreatic ductal adenocarcinoma.
Shares Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel, Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies, Dose reduction, interruption and discontinuation, Triple-negative breast cancer (TNBC).
Shares Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel, Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies, Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life, DPYD genotyping and DPD phenotyping before fluoropyrimidines.
Shares DPYD genotyping and DPD phenotyping before fluoropyrimidines, Dose reduction, interruption and discontinuation, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma.
Shares Sorafenib, Regorafenib, Colorectal cancer.
Shares Regorafenib, Cabozantinib, Colorectal cancer.